Studies focusing on the use of nonspecific modulators of immune activity such as IL-2 have demonstrated that creditable clinical responses can be achieved in certain tumour types, including melanoma and renal cell cancer (Fyfe et al, 1995; Atkins et al, 1999). This evidence concerns the gene IL2 and neoplasm.